Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

ABSTRACT:

Background

Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials that showed efficacy and manageable toxic effects.

Methods

In this multi-institutional phase 3 trial, we randomly assigned adults with heavily pretreated B-cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standard-of-care chemotherapy. The primary end point was overall survival.

Results

Of the 405 patients who were randomly assigned to receive blinatumomab (271 patients) or chemotherapy (134 patients), 376 patients received at least one dose. Overal

SUBMITTER: Kantarjian H 

PROVIDER: S-EPMC5881572 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature